Aline Corrêa Abrahão

Aline Corrêa Abrahão

Auto-generated profile, based on publicly available information

Aline Corrêa Abrahão

Department of Oral Diagnosis and Pathology, School of Dentistry, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Neoplasia
Verified
Journal Article
Open access
CSCristiane H Squarize
Cristiane H Squarize
RCRogerio Castilho
Rogerio Castilho
AAAline C Abrahao
Aline C Abrahao
AMAlfredo Molinolo
Alfredo Molinolo
MLMark W Lingen
Mark W Lingen
JGJ.Silvio Gutkind
J.Silvio Gutkind
The sequencing of the head and neck cancer has provided a blueprint of the most frequent genetic alterations in this cancer type. They include inactivating mutations in Notch, p53, and p16(ink4a) tumor suppressor genes, in addition to nonoverlapping activating mutations of the PIK3CA and RAS oncogenes or inactivation of the tumor suppressor gene PTEN. Notably, these genetic alterations, along with epigenetic changes, result in increased activity of phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is present in most head and neck squamous cell carcinomas (HNSCCs). Moreover, we show here that approximately 30% of HNSCCs exhibit reduced PTEN expression. We challenged the biologic relevance of this finding by combining the intraoral administration of a tobacco surrogate, 4-nitroquinoline 1-oxide, with a genetically defined animal model displaying reduced PTEN expression, achieved by the conditional deletion of Pten using the keratin promoter 14 CRE-lox system. This provided a specific genetic and environmentally defined animal model for HNSCC that resulted in the rapid development of oral-specific carcinomas. Under these experimental conditions, control mice did not develop HNSCC lesions. In contrast, most mice harboring Pten deficiency developed multiple SCC lesions in the lateral border and ventral part of the tongue and floor of the mouth, which are the preferred anatomic sites for human HNSCC. Overall, our study highlights the likely clinical relevance of reduced PTEN expression and/or inactivation in HNSCC progression, while the combined Pten deletion with exposure to tobacco carcinogens or their surrogates may provide a unique experimental model system to study novel molecular targeted treatments for HNSCC patients.

30 December 2013 in FEBS Open Bio
Verified
Journal Article
Open access
LALuciana Oliveira de Almeida
Luciana Oliveira de Almeida
AAAline C. Abrahao
Aline C. Abrahao
LRLuciana K. Rosselli-Murai
Luciana K. Rosselli-Murai
FGFernanda S. Giudice
Fernanda S. Giudice
Chiara ZagniChiara Zagni
Chiara Zagni
RCRogerio Castilho
Rogerio Castilho
Cisplatin‐based chemotherapy is the standard treatment of choice for head and neck squamous cell carcinoma (HNSCC). The efficiency of platinum‐based therapies is directly influenced by the development of tumor resistance. Multiple signaling pathways have been linked to tumor resistance, including activation of nuclear factor kappa B (NFκB). We explore a novel mechanism by which NFκB drives HNSCC resistance through histone modifications. Post‐translational modification of histones alters chromatin structure, facilitating the binding of nuclear factors that mediate DNA repair, transcription, and other processes. We found that chemoresistant HNSCC cells with active NFκB signaling respond to chemotherapy by reducing nuclear BRCA1 levels and by promoting histone deacetylation (chromatin compaction). Activation of this molecular signature resulted in impaired DNA damage repair, prolonged accumulation of histone γH2AX and increased genomic instability. We found that pharmacological induction of histone acetylation using HDAC inhibitors prevented NFκB‐induced cisplatin resistance. Furthermore, silencing NFκB in HNSCC induced acetylation of tumor histones, resulting in reduced chemoresistance and increased cytotoxicity following cisplatin treatment. Collectively, these findings suggest that epigenetic modifications of HNSCC resulting from NFκB‐induced histone modifications constitute a novel molecular mechanism responsible for chemoresistance in HNSCC. Therefore, targeted inhibition of HDAC may be used as a viable therapeutic strategy for disrupting tumor resistance caused by NFκB.

1 December 2010 in Oral Oncology
Verified
Journal Article
Closed access
AAAline Correa Abrahao
Aline Correa Abrahao
RCRogerio Castilho
Rogerio Castilho
CSCristiane H Squarize
Cristiane H Squarize
AMAlfredo A. Molinolo
Alfredo A. Molinolo
DSDecio dos Santos-Pinto
Decio dos Santos-Pinto
JGJ.Silvio Gutkind
J.Silvio Gutkind

30 December 2023 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
TFThamyres Campos Fonsêca
Thamyres Campos Fonsêca
LJLucas Alves Jural
Lucas Alves Jural
GMGuido Artemio Marañón-Vásquez
Guido Artemio Marañón-Vásquez
MMMarcela Baraúna Magno
Marcela Baraúna Magno
ARAna Luiza Oliveira Corrêa Roza
Ana Luiza Oliveira Corrêa Roza
AAAline Correa Abrahão
Aline Correa Abrahão

1 February 2011 in Brazilian Oral Research
Verified
Journal Article
Open access
PDF file
AAAline Correa Abrahao
Aline Correa Abrahao
BBBeatriz Venturi Bonelli
Beatriz Venturi Bonelli
FNFabio Daumas Nunes
Fabio Daumas Nunes
EDEliane Pedra Dias
Eliane Pedra Dias
MCMárcia Grillo Cabral
Márcia Grillo Cabral
Oral carcinogenesis is a multi-step process. One possible step is the development of potentially malignant disorders known as leukoplakia and erytroplakia. The objective of this study was to use immunohistochemistry to analyze the patterns of expression of the cell-cycle regulatory proteins p53 and p16INK4a in potentially malignant disorders (PMD) of the oral mucosa (with varying degrees of dysplasia) and in oral squamous cell carcinomas (OSCC) to correlate them with the expression of telomerase (hTERT). Fifteen PMD and 30 OSCC tissue samples were analyzed. Additionally, 5 cases of oral epithelial hyperplasia (OEH) were added to analyze clinically altered mucosa presenting as histological hyperplasia without dysplasia. p53 positivity was observed in 93.3% of PMD, in 63.3% of OSCC and in 80% of OEH. Although there was no correlation between p53 expression and the grade of dysplasia, all cases with severe dysplasia presented p53 suprabasal immunoexpression. p16INK4a expression was observed in 26.7% of PMD, in 43.3% of OSCC and in 2 cases of OEH. The p16INK4a expression in OEH, PMD and OSCC was unable to differentiate non-dysplastic from dysplastic oral epithelium. hTERT positivity was observed in all samples of OEH and PMD and in 90% of OSCC. The high hTERT immunoexpression in all three lesions indicates that telomerase is present in clinically altered oral mucosa but does not differentiate hyperplastic from dysplastic oral epithelium. In PMD of the oral mucosa, the p53 immunoexpression changes according to the degree of dysplasia by mechanisms independent of p16INK4a and hTERT.

1 April 2016 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
RCRomán Carlos
Román Carlos
BABruno Augusto Benevenuto de Andrade
Bruno Augusto Benevenuto de Andrade
NCNathalie Henriques Silva Canedo
Nathalie Henriques Silva Canedo
AAAline Corrêa Abrahão
Aline Corrêa Abrahão
MAMichelle Agostini
Michelle Agostini
MRMário José Romañach
Mário José Romañach